Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Vascular Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for VASN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VASN ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View VASN Products |
| Gene Delivery | VASN Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Preserves native conformation for cell-based assays. |
View VASN Products |
| Benchmark Ab | Anti-VASN (Sequence-verified Biosimilar) Recombinant positive control for assay validation. |
View VASN Products |
| Validator | VASN siRNA Set For knockdown verification and target specificity validation. |
View VASN Products |
| Related Target A | TGFB1 VASN acts as a negative regulator of TGF-beta signaling; co-targeting or pathway analysis is critical. |
View TGFB1 Products |
| Related Target B | ADAM17 The metalloprotease responsible for VASN shedding (releasing soluble sVASN decoy receptors). |
View ADAM17 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Shedding decoy interference (sVASN vs. membrane VASN) | Precisely truncated recombinant ECD proteins and full-length Lentivirus for stable cell line construction. |
| Cross-species validation (Human/Cyno/Mouse) | Orthologous VASN proteins available with >95% purity and verified theoretical molecular weight. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA included for specificity checks and target knockdown validation. |
Live VASN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for VASN therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and cell therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting the tumor microenvironment (TME) where VASN modulates TGF-beta signaling and drives epithelial-mesenchymal transition (EMT) in solid tumors such as hepatocellular carcinoma (HCC) and glioblastoma.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Oncology Biotechs | Hepatocellular Carcinoma, Glioblastoma | Internalization Assay (Need high-purity ECD-Fc & stable cell lines) |
| Monoclonal Antibody | Academic Institutes, Biopharma | Solid Tumors, Vascular Diseases | TGF-beta pathway blocking assay (Need functional screening tools) |
| CAR-T / Cell Therapy | Cell Therapy Developers | Glioblastoma, HCC | Target density & specificity validation (Need monomeric VASN proteins) |